A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of the Rivastigmine Patch in Japanese Patients with Alzheimer's Disease

BACKGROUND: As of 2010, the rivastigmine patch was licensed for the treatment of Alzheimer's disease (AD) in 64 countries. METHODS: This 24-week, multicenter, randomized, double-blind, placebo-controlled study evaluated the efficacy, safety and tolerability of the 5-cm(2) (9-mg loading dose; 4....

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamura, Yu, Imai, Yukimichi, Shigeta, Masahiro, Graf, Ana, Shirahase, Toru, Kim, Hyosung, Fujii, Akifumi, Mori, Joji, Homma, Akira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2011
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3199883/
https://www.ncbi.nlm.nih.gov/pubmed/22163242
http://dx.doi.org/10.1159/000328929

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3199883/
https://www.ncbi.nlm.nih.gov/pubmed/22163242
http://dx.doi.org/10.1159/000328929

Ejemplares similares